3D Showing of Mayzent Binding to Receptor Could Advance Treatments

For the first time, researchers have brought to light the precise three-dimensional structure of Mayzent (siponimod) as it binds to its molecular target, the sphingosine 1-phosphate receptor 1 (S1P1).

These findings are expected to aid in developing next-generation MS therapeutics with better selectivity for S1P1, enhancing their potency while reducing unwanted side effects, the researchers noted.

“This new structural information will help us develop the next generation of multiple sclerosis drugs,” Xin-Yun Huang, PhD, a professor of physiology and biophysics at Weill Cornell Medicine and a study co-lead author, said in a press release.

The study, “Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate,” was published in the journal Nature Communications.

Article source found here